Top

Published in:

01-06-2013 | REVIEW

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis

Authors: Alyssa Fischer, Shenhong Wu, Alan L. Ho, Mario E. Lacouture

Published in: Investigational New Drugs | Issue 3/2013

Summary

Axitinib is a potent, selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We have performed a systematic analysis to investigate the risk of hand-foot skin reaction (HFSR) to axitinib and compare the differences in incidences between sorafenib, sunitinib, pazopanib and axitinib. Relevant studies were identified from PubMed (1998–2012). Eligible studies were limited to prospective Phase II-III clinical trials in which cancer patients were treated with axitinib monotherapy at a starting dose of 5 mg orally twice daily. Incidence, relative risk (RR), and 95 % confidence intervals were calculated using random-effects or fixed-effects models based on heterogeneity of included studies. A total of 984 patients from 6 prospective clinical trials were included in the analysis. The overall incidence of all-grade and high-grade HFSR was 29.2 % (95 % CI: 14.0–51.1 %) and 9.6 % (95 % CI: 4.2–20.7 %), respectively. The relative risks of all-grade and high-grade HFSR to axitinib compared to sorafenib were decreased for all-grade (RR = 0.54, 95 % CI: 0.44–0.65, p < 0.001) and high-grade HFSR (RR = 0.31, 95 % CI: 0.19–0.52, p < 0.001). The risk of all-grade and high-grade HFSR to axitinib, sunitinib and sorafenib was significantly higher as compared to pazopanib (RR = 6.49, 95 % CI: 4.65–9.05, p < 0.001; RR = 6.40, 95 % CI: 3.60–11.37, p < 0.001, and RR = 4.20, 95 % CI: 3.07–5.75, p < 0.001; RR = 3.67, 95 % CI: 2.15–6.24, p < 0.001, and RR = 7.51, 95 % CI: 5.5–10.3, p < 0.001; RR = 5.93, 95 % CI: 3.5–10.0, p < 0.001, respectively). Similar to sorafenib and sunitinib, axitinib is associated with a significant risk of HFSR, despite having an increased specificity for VEGF receptors. These findings underscore the importance of supportive dermatologic care in patients treated with axitinib, in order to maintain quality of life, adherence, and persistence to therapy.

Igarashi H, Esumi M, Ishida H, Okada K (2002) Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95(1):47–53. doi:10.1002/cncr.10635 PubMedCrossRef

Sawhney R, Kabbinavar F (2008) Angiogenesis and angiogenic inhibitors in renal cell carcinoma. Curr Urol Rep 9(1):26–33PubMedCrossRef

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 27(22):3584–3590. doi:10.1200/JCO.2008.20.1293 CrossRef

Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G (2007) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178(5):1883–1887. doi:10.1016/j.juro.2007.07.030 PubMedCrossRef

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. doi:10.1056/NEJMoa060655 PubMedCrossRef

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol: Off J Am Soc Clin Oncol 28(6):1061–1068. doi:10.1200/JCO.2009.23.9764 CrossRef

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, Investigators AT (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111. doi:10.1016/S0140-6736(07)61904-7 PubMedCrossRef

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol: Off J Am Soc Clin Oncol 26(33):5422–5428. doi:10.1200/JCO.2008.16.9847 CrossRef

Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O’Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res: Off J Am Assoc Cancer Res 14(22):7272–7283. doi:10.1158/1078-0432.CCR-08-0652 CrossRef

10.

U.S. Food and Drug Administration (2011) FDA Briefing Document, Oncologic Drugs Advisory Committee Meeting, NDA 20324 Axitinib (Inlyta). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm282290.pdf. Accessed 12 Nov 2012

11.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939. doi:10.1016/S0140-6736(11)61613-9 PubMedCrossRef

12.

Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371(9630):2101–2108. doi:10.1016/S0140-6736(08)60661-3 PubMedCrossRef

13.

Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. The Lancet Oncol 12(3):256–262. doi:10.1016/S1470-2045(11)70004-3 CrossRef

14.

Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O (2011) Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res: Off J Am Assoc Cancer Res 17(23):7462–7469. doi:10.1158/1078-0432.CCR-11-0534 CrossRef

15.

Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol: Off J Am Soc Clin Oncol 27(23):3836–3841. doi:10.1200/JCO.2008.20.8355 CrossRef

16.

Rini BI, Grünwald V, Fishman MN, Melichar B, Ueda T, Karlov PA, Bair AH, Chen Y, Kim S, Jonasch E, Cleveland Clinic Taussig Cancer Institute C, OH, Hannover Medical School H, Germany, H. Lee Moffitt Cancer Center & Research Institute T, FL, University Hospital O, Czech Republic, Division of Urology CCC, Chiba, Japan, City Clinical Oncology Dispensary SP, Russia, Pfizer Oncology SD, CA, University of Texas M. D. Anderson Cancer Center H, TX (2012) Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 30, 2012 (suppl; abstr 4503)

17.

ClinicalTrials.gov. Available at http://www.clinicaltrials.gov. Accessed 10 Nov 2012

18.

Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, Lacouture ME (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol: JDD 11(11):e61–e65PubMed

19.

Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taieb C (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16(10):1469–1478. doi:10.1634/theoncologist.2011-0033 PubMedCrossRef

20.

Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9):1001–1011. doi:10.1634/theoncologist.2008-0131 PubMedCrossRef

21.

Balagula Y, Lacouture ME, Cotliar JA (2010) Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 8(4):149–161PubMed

22.

Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 19(11):1955–1961. doi:10.1093/annonc/mdn389 CrossRef

23.

Sonpavde G, Hutson TE, Rini BI (2008) Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 17(5):741–748. doi:10.1517/13543784.17.5.741 PubMedCrossRef

24.

Chu D, Lacouture ME, Fillos T, Wu S (2008) Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 47(2):176–186. doi:10.1080/02841860701765675 PubMedCrossRef

25.

Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7(1):11–19. doi:10.3816/CGC.2009.n.002 PubMedCrossRef

26.

Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME (2012) The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investig New Drugs 30(4):1773–1781. doi:10.1007/s10637-011-9652-2 CrossRef

27.

Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol: Off J Am Soc Clin Oncol 26(29):4708–4713. doi:10.1200/JCO.2007.15.9566 CrossRef

28.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 27(27):4462–4468. doi:10.1200/JCO.2008.21.7034 CrossRef

29.

Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet Oncol 8(11):975–984. doi:10.1016/S1470-2045(07)70285-1 CrossRef

30.

Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H (2011) Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 47(17):2592–2602. doi:10.1016/j.ejca.2011.07.014 PubMedCrossRef

31.

Inlyta® (axitinib) tablets [full prescribing information]. New York: Pfizer, 2012.

32.

van Geel RM, Beijnen JH, Schellens JH (2012) Concise drug review: pazopanib and axitinib. Oncologist 17(8):1081–1089. doi:10.1634/theoncologist.2012-0055 PubMedCrossRef

33.

U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (9 Aug 2006) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf Accessed 5 Nov 2012.

34.

Porta C, Paglino C, Imarisio I, Bonomi L (2007) Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin exp Med 7(4):127–134. doi:10.1007/s10238-007-0145-8 PubMedCrossRef

35.

Autier J, Escudier B, Wechsler J, Spatz A, Robert C (2008) Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 144(7):886–892. doi:10.1001/archderm.144.7.886 PubMedCrossRef

36.

Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158(3):592–596. doi:10.1111/j.1365-2133.2007.08357.x PubMedCrossRef

37.

Huggins RH, KuzelTM, Anderson RT, West DP, Lacouture ME (2008) Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL). J Clin Oncol 26: 2008 (suppl; abstr 16122)

38.

Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 15(4):1411–1416. doi:10.1158/1078-0432.CCR-08-1141 CrossRef

39.

Lacouture ME, Boerner SA, Lorusso PM (2006) Non-rash skin toxicities associated with novel targeted therapies. Clin Lung Cancer 8(Suppl 1):S36–S42PubMedCrossRef

40.

Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res: CR 29:95. doi:10.1186/1756-9966-29-95 PubMedCrossRef

41.

Gomez P, Lacouture ME (2011) Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 16(11):1508–1519. doi:10.1634/theoncologist.2011-0115 PubMedCrossRef

42.

Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB (2007) Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 12(10):1178–1182. doi:10.1634/theoncologist.12-10-1178 PubMedCrossRef

43.

Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B (2006) Pooled safety analysis of BAY 43–9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 42(4):548–556. doi:10.1016/j.ejca.2005.11.014 PubMedCrossRef

44.

Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, Sterry W, Lademann J (2005) Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol: Off J Eur Soc Med Oncol/ESMO 16(7):1210–1211. doi:10.1093/annonc/mdi204 CrossRef

45.

Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH (2010) Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30(1):52–56. doi:10.1592/phco.30.1.52 PubMedCrossRef

46.

Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol: Off J Am Soc Clin Oncol 24(1):25–35. doi:10.1200/JCO.2005.02.2194 CrossRef

47.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24):11851–11858. doi:10.1158/0008-5472.CAN-06-1377 PubMedCrossRef

48.

Rosen A, Balagula Y, Goldfarb S, Lacouture ME (2012) Dermatologic Adverse Events during Treatment. In: Berger AM, Shuster JL, Von Roenn JH (eds) Principles and Practice of Palliative Care and Supportive Oncology, 4e, Philadelphia. Wolters Kluwer Health / Lippincott Williams & Wilkins, pp 333–347

49.

Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G (2005) Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 74(2):121–123. doi:10.1111/j.1600-0609.2004.00351.x PubMedCrossRef

50.

Schenone S, Bondavalli F, Botta M (2007) Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem 14(23):2495–2516PubMedCrossRef

51.

Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME (2012) Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 97(4):1125–1133. doi:10.1210/jc.2011-2677 PubMedCrossRef

52.

Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anti-Cancer Drugs 20(1):81–82. doi:10.1097/CAD.0b013e3283161012 PubMedCrossRef

53.

Lim WT, Ng QS, Ivy P, Leong SS, Singh O, Chowbay B, Gao F, Thng CH, Goh BC, Tan DS, Koh TS, Toh CK, Tan EH (2011) A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 17(16):5481–5489. doi:10.1158/1078-0432.CCR-10-3409 CrossRef

54.

Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H (2010) The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40(10):980–985. doi:10.1093/jjco/hyq073 PubMedCrossRef

55.

Zhang H, Dong B, Lu JJ, Yao X, Zhang S, Dai B, Shen Y, Zhu Y, Ye D, Huang Y (2009) Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 9:249. doi:10.1186/1471-2407-9-249 PubMedCrossRef

56.

Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. The Lancet Oncol 6(7):491–500. doi:10.1016/S1470-2045(05)70243-6 CrossRef

57.

Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME (2012) Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 23(8):2103–2108. doi:10.1093/annonc/mdr580 CrossRef

58.

Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME (2009) Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 14(3):291–302. doi:10.1634/theoncologist.2008-0237 PubMedCrossRef

59.

Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, Song T, Zhou W, Wang H, Yang W, Wang X, Yang Y, Shi L, Bai Y, Ye S, Zhongshan Hospital FU, Shanghai, China, The Third Affiliated Hospital of Sun Yat-sen University G, China, 301 Military Hospital B, China; Liver Transplantation Center of the 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University S, China, Guangdong Provincial People’s Hospital G, China, Tianjin Cancer Hospital T, China; Eastern Hepatobiliary Hospital of the Second Military Medical University, Shanghai, China, Jilin Provincial Tumor Hospital J, China, Union Hospital of Fujian Medical University F, China, The 81 Hospital of the Chinese People’s Liberation Army N, China, 302 Military Hospital of China B, China, Heilongjiang Provincial Cancer Hospital H, China (2012) A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. J Clin Oncol 30, 2012 (suppl; abstr 4008)

60.

Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S (2008) Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol 47(5):843–851. doi:10.1080/02841860802047395 PubMedCrossRef

61.

U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 5 Nov 2012

Title: The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
Authors: Alyssa Fischer
Shenhong Wu
Alan L. Ho
Mario E. Lacouture
Publication date: 01-06-2013
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-013-9927-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2013

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas

Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction

Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells

Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer